Inlyta

Axitinib, the active ingredient in Inlyta, is a selective tyrosine kinase inhibitor presented as an oral tablet for systemic use. It is indicated for the treatment of metastatic renal cell carcinoma in adult patients, where it helps to inhibit tumor‑driven blood vessel formation by targeting vascular endothelial growth factor receptors, reducing angiogenesis and tumor progression.

GNH USA supplies Inlyta as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, and pharmacies worldwide, providing reliable access to this oncology medication.

Inlyta (axitinib) is used in the management of cancers that rely on VEGF‑driven angiogenesis.

Metastatic renal cell carcinoma: improves progression‑free survival in adults with advanced disease. Advanced renal cell carcinoma after prior therapy: offers an additional treatment option when first‑line agents have failed. Renal cell carcinoma with VEGF pathway activation: targets angiogenesis to slow tumor growth.

Common Side Effects: - Hypertension: elevated blood pressure requiring monitoring and management. - Diarrhea: may be mild to moderate and manageable with supportive care. - Fatigue: persistent tiredness affecting daily activities. - Nausea: occasional upset stomach or vomiting.

Serious or Rare Side Effects: - Arterial thromboembolism: risk of blood clots in arteries. - Gastrointestinal perforation: rare but severe gut wall injury. - Severe hemorrhage: potentially life‑threatening bleeding events.

Patients receiving Inlyta should be monitored for several safety considerations. - Monitor blood pressure: check regularly and treat hypertension promptly. - Assess liver function: evaluate hepatic enzymes before and during therapy. - Evaluate wound healing: postpone elective surgery while on treatment. - Review cardiovascular risk: use caution in patients with prior thromboembolic events. - Store at ambient temperature: keep below 25°C in the original packaging, protect from moisture.

Axitinib may interact with other medicines that affect its metabolism or increase bleeding risk.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): increase axitinib exposure. - Strong CYP3A4 inducers (e.g., rifampin): decrease axitinib exposure. - Potent CYP3A4 substrates with narrow therapeutic index: risk of altered levels.

Moderate Interactions (Monitor Closely): - Antihypertensive agents: additive blood‑pressure lowering effect. - Anticoagulants (e.g., warfarin): may increase bleeding tendency. - Non‑steroidal anti‑inflammatory drugs (NSAIDs): elevate risk of gastrointestinal bleeding. - Other VEGF pathway inhibitors: potential for overlapping toxicities.